Authum Investment & Infrastructure Limited has informed the Exchange about Agreements
AIIL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Authum Investment & Infrastructure Limited (AIIL) has signed a Share Subscription cum Purchase Agreement (SSPA) with Rivaara Labs Private Limited and its promoter to acquire a 35.09% stake in the diagnostics company. The total deal value is Rs. 36.57 crore, comprising Rs. 36 crore as primary infusion into 3.6 crore compulsorily convertible preference shares (CCPS) and Rs. 56.83 lakh for purchasing existing equity shares and CCPS from current shareholders. Rivaara Labs operates in the diagnostics space (pathology, imaging, PCR testing, genomic sequencing, RT-PCR kits, and digital healthcare) with FY25 turnover of Rs. 25.53 crore and negative net worth of Rs. 34.83 crore. The transaction is expected to close by September 30, 2025, is a cash deal, and is not a related-party transaction.
This is a portfolio diversification move into the healthcare diagnostics sector, but the deal size is modest relative to AIIL's scale and the target has declining revenues and negative net worth, so near-term impact on the stock is likely limited. The stake of 35.09% keeps AIIL just below the open-offer threshold, making this a strategic minority investment rather than a control acquisition.